The ability to introduce DNA, RNA or proteins into cells to alter their genotype or phenotype (a process called transfection) is crucial in a variety of life science applications. Various types of transfection methods exist and choosing which approach to use often depends on its suitability to the application in question. Electroporation is a physical transfection method that permeabilizes the cell membrane by applying an electrical pulse and moves molecules via the electrical field into the cell. It is a powerful tool for transfecting large DNA fragments and achieving good transfection efficiencies in cell lines. However, due to high toxicity traditional electroporation has been less successful for efficiently transfecting more biologically relevant primary cells and stem cells, which has limited its application.
Our solution is an improved electroporation technology, the Nucleofector® Technology, originally introduced into the market by legacy Amaxa in 2001. It enables highly efficient, transfection of primary cells, stem cells, neurons, and cell lines that have traditionally been difficult to transfect via electroporation and other non-viral transfection methods. In recent years, this has opened novel opportunities for disease research and therapeutic development, including the advancement of gene therapies, immunotherapies, and stem cell generation.
In the following sections, we provide an overview of Nucleofector® Technology, and explore what benefits it can bring to your research over traditional electroporation methods. We also summarize the transfection capabilities and flexible scaling offered by our various Nucleofector® Platforms, to help you choose which one is best suited to your specific application. This can ensure you obtain the very highest levels of transfection efficiency and quality for your research.
